• Our proprietary 3-dimensional,
    spherical nucleic acid (SNA™)
    architecture unlocks the potential
    of therapeutic oligonucleotides
    in a wide range of cells and tissues.

  • Our lead programs
    address inflammatory diseases,
    genetic disorders and oncology.

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in wide range of cells and tissues.